A 21-month-o!d girl with neuroblastoma developed chronic verrucous Oka strain varicella-zoster infection during chemotherapy. Virus isolated from the patient demonstrated high-level acyclovir resistance, and its thymidine kinase had no in vitro enzymatic activity. After foseamet therapy, she underwent stem cell transplantation without varicella reactivation. This is only the second reported case of resistant varicella zoster virus caused by Oka strain virus.
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The varicella zoster virus vaccine strain Oka (V-Oka) is highly attenuated and can prevent severe disease associated with varicella infection. However, in rare instances it can cause disseminated infections in immunosuppressed patients that require prompt and prolonged therapy.
CASE REPORT
A 21-month-old girl was diagnosed with stage IV neuroblastoma. She had received varicella immunization in her left thigh 946 approximately I week before diagnosis and had no other known history of varicella exposure. Her chemotherapy plan consisted of a combination of 4 courses of cyclophosphamide, adriamycin, and vincristine (CA V) and 2 courses of cisplatin and etoposide (CDDP-E) to be followed by autologous stem cell transplant.
Four weeks into chemotherapy, during a period of leukocyte recovery, the patient developed 2 erythematous, umbilicated papules on her right finger and right lower abdomen distant from the immunization site. In the ensuing week, these lesions evolved into vesicular patches, primarily involving her hands, right leg, and abdomen. Serum anti-varicella IgG was positive at this time and polymerase chain reaction (PCR) of lesion scrapings was positive for varicella zoster virus (VZV). Intravenous acyclovir (IV ACV) was started at 60 mglkgld and the lesions improved after I week of IV therapy. Over the next 2 weeks, therapy was changed to oral ACV therapy at 2 separate times (90 mglkgld and later 30 mgikgld), but readmission was required for IV therapy within 2 days each time because of worsening lesions and missed oral doses as a result of emesis. Finally, IV ACV (60-70 mgikgld) was restarted and continued for 3 additional weeks. During the 5 weeks of IV and oral ACV therapy, the lesions became verrucous and dusky but never healed completely (Fig. I , http://links.lww.comlA481), and new vesicles continued to erupt intermittently, primarily on her right leg and lower abdomen.
VZV was isolated from a newly erupted vesicle, and this isolate exhibited high level resistance in vitro to both ACV and pcneiclovir ( After completing induction chemotherapy and eonsolidative radiotherapy, she remained in remission on 13-cis retinoic acid for 
MATERIALS AND METHODS
Virus Purificatio/l alld Characterizatio/l. Varicella-zoster stmin Oka was obtained from Amcrican Type Culture Collection (Manassas, VA) and passaged as described previously. I The clinical isolate 6/06/2 was obtained from a swab of unroofed lesions from the patient. This isolate was plaeed in 25 cm2 flasks with freshly trypsinized primary human foreskin fibroblast cells. Infected cells were passaged and expanded to produce virus stocks for subsequent studies. Susceptibility to antiviral drugs was determined by plaque reduction assay with methods described previously.2 Drugs were obtained from the NIAID or purchased from Sigma Aldrich (St. Louis, MO). Cidofovir was a gift from Mick Hitchcock at Gilead Sciences (Foster City, CA).
Viral DNA was extracted from cells infected with Oka or 06/06/2 by standard methods. The TK gene was amplified using primers 5'-CAC CAT GTC AAC GGA TAA AAC CGA TGT AA-3' and 5'-GGA AGT GTT GTC CTG AAC GGC ATT-3'; ORF62 was amplified using primers 5' -AAG TTG GCA AAC GCA GTC-3' and 5'-ATT ACT GTC GAC CCG AGA CC-3' and ORF28 was amplified using primers 5'-ATG TCA TCG TTT CAA TTT TTG G-3' and 5'-TTA ACT TTG ATG GAG AAT TGC TTT TGG-3'. Resulting PCR products were sequenced using a set of internal primers to sequence both strands of the DNA. The TK open reading frames from both strains were cloned into the pETI51d bacterial expression vector (Invitrogen, Carlsbad CA) and the open reading frames were completely sequenced. The enzymes from both strains of VZV werc expressed in Escherichia coli BL21 cells and were purified and assayed by methods described previously.3 Briefly, enzymatic activity was dctermined in a luciferase assay using thymidine as a substrate and used ATP consumption as a marker for enzymatic activity.
RESULTS

Susceptibility 10
Alllh'iral Drugs. The clinical isolate (6/06/2) was cultured, amplified, and its susceptibility to a set of representative antiviral drugs was deternlined by standard plaque assay using Oka as a fully susceptible control virus. The 6/06/2 isolate was fully susceptible to both foscamet and cidofovir, whereas it was modestly resistant to ganciclovir (GCV) and highly resistant to both ACV and penciclovir (PCV) ( Table I) . These results seem to be consistent with the clinical course including the inability of ACV to limit the infection. Molecl/lar Characterizatioll of 06/06/2. Significant differences were observed in drug sensitivity between the clinical isolate and the Oka strain. Initial studies sought to confirm that the clinical specimen was derived from the vaccine strain. A previous report identified a polymorphism diagnostic of the vaccine strain, which is used by the vaccine manufacturer to confirm vaccine strain identity." This region of the clinical isolate was sequenced and did contain a Smal site characteristic of thc Oka strain, indicating that the patient's isolate \Vas derived from the vaccine virus. To characterize the mutations that the strain acquired to become resistant to the drugs, the coding © 2008 Lippillcott Williams & Wilkins regions of the TK and polymerase genes \\'ere completely sequenced. A single mutation was observed in 06/06/2, resulting in a T256A mutation in the amino acid sequence of the TK. Scven additional mutations were also identified in the coding sequence of the viral DNA polymerase. Amino acid mutations identified were Q452R in region IV, C566Y and 1593V in D-region C, and L703S and N887S in regions II and I, respcctively.s Two additional mutations, VI221 and F182R, were also observed in the amino terminus of the polymerase. Mutations that confer resistance to ACV have been identified previously in the carboxyl terminus of the TK open reading frame near the T256A mutation in this isolate. To confirm that this mutation contributed to drug resistance, the open reading frames from Oka and from 06/06/2 \\'ere cloned into a baeterial expression vector, expressed in bacteria, and purified. The enzyme exprcssed from the Oka open reading frame was highly active with thymidine as a substrate and had a Vmu.
• of 6.8 J.LM min -I J.Lg -I, whereas the enzyme expressed from the 06/06/2 ORF did not exhibit detectable activity «0.25 J.LM min-I J.Lg-I). Thus this mutation is likely sufficient to explain the observed resistance to ACV, PCV, and GCV that each require phosphorylation by this viral enzyme. The additional mutations in the polymerase gene are also similar to those reported in drug resistant strains, but \\'ere not investigated further. The TK mutation in this isolate is likely sufficient for the high level of antiviral resistance observed for this virus.
DISCUSSION
This case represents a sccond report describing chronic disseminated varicella disease caused by acyclovir-resistant Oka strain VZV, but it is the first to document recovery of a repiicationcompetent Oka strain viral isolate from a patient. The only other published report of acyclovir-resistant Oka strain VZV also occurred in a l-year-old child who began chemotherapy for neuroblastoma shortly after administration of the varicella vaccine." In both cases, the hyperkeratotic, verrucous appearance of the patient's rash is consistent with the well-described clinical entity of chronic, ACVresistant wild-type VZV infection in immunocompromised patients. [6] [7] [8] [9] The clinical appearance of this rash should thus alert the clinician to the possibility of antiviral-resistant VZV, even if disease is believed to be eaused by Oka strain varicella.
This ease is the first report of a live viral isolate derivcd from Oka strain recovered and characterized from a patient with clinical suspicion for antiviral resistance, demonstrating in vivo viral replication during ACV therapy. In prior reports, DNA was isolated from elinicallesions and antiviral sensitivity was characterized based on the DNA sequences. Our inabiJity to recovcr infectious virions from skin lesions after initiation of foscarnct therapy suggests that foscarnct was able to limit viral replication in vivo, although the patient failed to achieve complete resolution of symptoms until cessation of chcmotherapy and reconstitution of the immune system.
The Oka strain varicella vaccine is highly attenuated and is generally accepted as safe in immune-competent individuals 10.11; however, its use is restricted in those with impaired cellular immunity or in close family eontacts of such patients.12.13 Current recommendations state to withhold vaccination in patients with leukemia, lymphoma, or other malignancies in remission until at least 3 months after cessation of chemotherapy.12 These 2 cases ofrcsistant vaccine strain varicella in patients with malignancy argue the nccd for particular attention regarding status of varicella vaccination history at the time of cancer diagnosis in pediatric paticnts. Some experts recommend initiating prophylactic oral ACV (80 mglkg/d) if an immunosuppressive event occurs within 4-6 weeks ofvaccination and continuing ACV prophylaxis until completion of chemotherapy or the immunosuppressive event. Prompt treatment with 
